Baseline quality of life predicts overall survival in patients with mCRPC treated with
Journal
Hellenic journal of nuclear medicine
ISSN: 1790-5427
Titre abrégé: Hell J Nucl Med
Pays: Greece
ID NLM: 101257471
Informations de publication
Date de publication:
Historique:
received:
23
12
2019
accepted:
10
03
2020
pubmed:
31
3
2020
medline:
2
2
2021
entrez:
31
3
2020
Statut:
ppublish
Résumé
The prognostic value of baseline clinical parameters in predicting the survival prolonging effect of radium-223-dichloride ( One hundred and seventy-three consecutive mCRPC patients treated with On multivariate analysis, baseline patients' hemoglobin (Hb), total alkaline phosphatase (tALP), and two EORTC QLQ-C30 items, physical functioning (HR=0.970,CI=0.960-0.980, P<0.001) and dyspnea (HR=0.992,CI=0.986-0.999, P=0.023), were significantly associated with OS. In the resulting model of the multivariate analysis performed after PCA, baseline patients' Hb, tALP and QoL-score were independent significant predictors of OS (QoL-score: HR=0.995-95%CI=0.992 - 0.998, P=0.001). The OS analysis stratified by score of baseline QoL, showed a median OS of 8 (95%CI=6-11) and 16 (95%CI=12-24) months for scores respectively below and above the cut-off value (log-rank-P<0.001). The joint model showed a significant deterioration of QoL-score during both Baseline QoL is a significant predictor of OS, meaning that patients with better pretreatment QoL are more likely to obtain a marked survival prolonging effect from
Identifiants
pubmed: 32222727
pii: s002449912001
doi: 10.1967/s002449912001
doi:
Substances chimiques
Radioisotopes
0
radium Ra 223 dichloride
RJ00KV3VTG
Radium
W90AYD6R3Q
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM